Skip to main content
Aimee Talleur, MD
Aimee C. Talleur, MD

Aimee C. Talleur, MD

Assistant Member, St. Jude Faculty

  • Fellowship Director, BMTCT Fellowship Program



BA - Union College, Schenectady, NY
MD - State University of New York Upstate Medical University, Syracuse, NY
Pediatric Residency – Children’s National Medical Center, Washington DC
Pediatric Hematology-Oncology FellowshipSt. Jude Children’s Research Hospital
Pediatric Bone Marrow Transplantation and Cellular Therapy Fellowship - St. Jude Children’s Research Hospital

Research Interests

  • Cancer immunotherapy
  • Adoptive cell therapy
  • Clinical investigation of chimeric antigen receptor therapies

Selected Publications

Epperly R, Shulkin BL, Bag AK, Cheng C, Inaba H, Lucas JT, Naik S, Triplett BM, Gottschalk S, Talleur AC. CD19-CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL. Blood Adv Aug 18, 2023.

Wilson TL, Kim H, Chou CH, Langfitt D, Mettelman RC, Minervina AA, Allen EK, Metais JY, Pogorelyy MV, Riberdy JM, Velasquez MP, Kottapalli P, Trivedi S, Olsen SR, Lockey T, Willis C, Meagher MM, Triplett BM, Talleur AC, Gottschalk S, Crawford JC, Thomas PG. Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T cell receptor lineages. Cancer Discov Jul 2022.

Talleur A, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman AY, Srinivasan A, Velasquez MP, Obeng EA, Willis CM, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou S, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood BA, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Adv Apr 2022.

Maron GM, Hijano DR, Epperly R, Su Y, Tang L, Hayden RT, Naik S, Karol SE, Gottschalk S, Triplett BM, Talleur AC. Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy. Front Oncol 12:845540, 2022.

Kim-Hoehamer YI, Riberdy JM, Zheng F, Park JJ, Shang N, Métais JY, Lockey T, Willis C, Akel S, Moore J, Meagher MM, Velasquez MP, Triplett BM, Talleur AC, Gottschalk S, Zhou S. Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Ther Jan 8, 2022.

Ravich JW, Huang S, Zhou Y, Brown P, Pui CH, Inaba H, Cheng C, Gottschalk S, Triplett BM, Bonifant CL, Talleur AC. Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel. Transplant Cell Ther Dec 4, 2021.

Hines MR, Keenan C, Maron Alfaro G, Cheng C, Zhou Y, Sharma A, Hurley C, Nichols KE, Gottschalk S, Triplett BM, Talleur AC. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol July 2021.

Hashmi SK, Harstead E, Sachdev M, Black DD, Clark I, Ortanca I, Triplett BM, Talleur AC. Hematopoietic cell transplant for reversal of liver fibrosis in a pediatric patient with erythropoietic protoporphyria. Pediatr Transplant Jan 6;e13966, 2021. doi: 10.1111/petr.13966. Online ahead of print.

Mo G, Wang HW, Talleur AC, Shahani SA, Yates B, Shalabi H, Douvas MG, Calvo KR, Shern JF, Chaganti S, Patrick K, Song Y, Fry TJ, Wu X, Triplett BM, Khan J, Gardner RA, Shah NN. Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. J Immunother Cancer Nov;8(2):e001563, 2020. doi: 10.1136/jitc-2020-001563.

Talleur AC, Flerlage JE, Shook DR, Chilsen AM, Hudson MM, Cheng C, Huang S, Triplett BM. Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: A single institutional experience. Bone Marrow Transplant. Apr 9, 2020. doi: 10.1038/s41409-020-0879-4. [Epub ahead of print]

Levine DR, Van Noy K, Talleur AC, Snyder A, Kaye EC, Baker JN. Thoughts from the threshold: Patient and family hopes, fears, values, and goals at the onset of pediatric hematopoietic cell transplantation. Bone Marrow Transplant Jun;55(6):1103-1113, 2020. doi: 10.1038/s41409-020-0794-8. Epub Jan 28, 2020.

Epperly R, Furman W, Hines M, Santiago T, Li Y, Madden R, Mamcarz E, Cervi D, Federico S, Triplett B, Talleur A. Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma. Pediatr Blood Cancer Nov;66(11):e27964, 2019. doi: 10.1002/pbc.27964. Epub 2019 Aug 12.

Talleur AC, Metais JY, Li Y, Throm RE, Tillman H, Rooney B, Moustaki A, Leung W. Allogeneic CD27-depleted cells in adoptive cell therapy. Adv Cell Gene Ther 2(2):e45, 2019.

Talleur AC, Triplett BM, Federico S, Mamcarz E, Janssen W, Wu J, Shook D, Leung W, Furman WL. Consolidation therapy for newly diagnosed pediatric high-risk neuroblastoma patients using busulfan/melphalan, autologous hematopoietic cell transplant, anti-GD2 antibody, GM-CSF, IL-2 and haploidentical NK cells. Biol Blood Marrow Transplant Nov;23(11):1910-1917, 2017.

Snaman JM, Talleur AC, Lu J, Levine DR, Kaye EC, Sykes A, Lu Z, Triplett BM, Baker JN. Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. Bone Marrow Transplant Nov 13, 2017.

Full list of publications

Last update: September 2023